Blood Test NMAP Levels in Newly Diagnosed Kidney Cancer Patients
Compares NMAP blood levels in adults with new kidney cancer and people without it.
Plain-language title generated from the registry record
Registry title: Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
Key facts
- Where
- Shanghai, ChinaSee the site
Where in China
- Xinhua Hospital Affiliated to Shanghai Jiaotong University School of MedicineShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Trial code
- NCT04113486
- Record updated
- 29 July 2026
- Original description
This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.Read full original descriptionShow less
Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations
This study aims to observe the difference between NMAP (nicotinamide metabolism associated protein) serum levels in primary diagnosed renal cancer patients and non-renal cancer patient controls, plot the ROC curve and establish appropriate cut-off values.
Inclusion: The tumor group patients were found to have renal or hepatic mass, plan to receive surgical treatment (except for radiofrequency ablation, cryoablation, etc., which were not available for pathological examination). The control group patients were ruled out of tumor based on radiological tests and commonly used tumor biomarkers; Age ≥ 18 years old and able to provide written informed consent; Have not received any systemic or topical treatment for kidney/liver tumors; Cardiopulmonary, liver and kidney functions are able to tolerate surgery and can comply with research requirements.
Exclusion: The investigators believe that the subject may be unsuitable for inclusion due to severe concurrent diseases, infections, and etc; Major surgery (surgery requiring general anesthesia) was performed within 4 weeks prior to screening visits; The subjects is known or suspected of other malignancies; There has been another history of malignancy in the past 5 years.